Company Filing History:

4 out of 1,747

Mayo Foundation for Medical Education and Research

J. B. Tillott Limited

patent

4. 4 out of 832,912

Other

patents

Years Active: 1980-2004

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6734188 - Composition for treatment of constipation and irritable bowel syndrome (2004-05-11),

2. 6238689 - Intestinal absorption of nicotine to treat nicotine responsive conditions (2001-05-29),

3. 6166044 - Colonic delivery of nicotine to treat inflammatory bowel disease (2000-12-26),

4. 6071959 - Pharmaceutical products containing a complex of an amide-type local (2000-06-06),

5. 5889028 - Colonic delivery of nicotine to treat inflammatory bowel disease (1999-03-30),

6. 5846983 - Colonic delivery of nicotine to treat inflammatory bowel disease (1998-12-08),

7. 5843482 - Products and processes for the treatment of the alimentary canal (1998-12-01),

8. 5541171 - Orally administrable pharmaceutical composition (1996-07-30),

9. 5541170 - Orally administrable pharmaceutical compositions (1996-07-30),

10. 5401512 - Delayed release oral dosage forms for treatment of intestinal disorders (1995-03-28),

11. 4687667 - Method of treating functional bowel disorders by the administration of (1987-08-18),

12. 4222923 - Adhesive composition and method of use (1980-09-16),

Title: Innovations by John Rhodes in Medical Treatments

Introduction

John Rhodes is a notable inventor based in Cardiff, GB, recognized for his contributions to medical treatments. With a total of 12 patents to his name, he has made significant strides in addressing various health conditions through innovative compositions.

Latest Patents

Among his latest patents, Rhodes has developed a composition for the treatment of constipation and irritable bowel syndrome. This composition utilizes a delayed and sustained release of an opioid antagonist, which begins its release in the mid to distal small intestine or ascending colon. It provides sustained release throughout the remaining parts of the small intestine and colon. Preferred opioid antagonists for this treatment include naloxone and naltrexone. Another significant patent involves the intestinal absorption of nicotine to treat nicotine-responsive conditions. This composition delivers nicotine systemically in therapeutic amounts while avoiding peak plasma levels that can lead to addiction and toxic side effects. The delivery method is designed for absorption predominantly from the colon.

Career Highlights

Rhodes has had a distinguished career, working with reputable organizations such as the Mayo Foundation for Medical Education and Research. His work has focused on developing innovative solutions to improve patient outcomes in gastrointestinal health.

Collaborations

Throughout his career, Rhodes has collaborated with esteemed colleagues, including Brian K. Evans and William J. Sandborn. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

John Rhodes stands out as an influential inventor in the field of medical treatments, with a focus on innovative compositions that address significant health issues. His work continues to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com